The Covid-19 pill from Pfizer Inc. failed to prevent symptomatic infections in adults who had been exposed to the pandemic virus, a late-stage study found.

Pfizer said Friday that the drug, named Paxlovid, failed the study’s main objective of meaningfully reducing the risk of confirmed and symptomatic Covid-19 infections in adults who were exposed to the virus by someone in their household.

To Read the Full Story

This post first appeared on wsj.com

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

In Bucha, where Russian war crimes are suspected, civilians say they saw ‘horrific things’

The family agonized over when they should flee, trying to come to…

Anti-abortion groups urge court to let abortion pill ruling stand

The anti-abortion groups at the center of the Texas lawsuit over a…

Boston Dynamics unveils new Atlas robot for commercial use

Boston Dynamics unveiled Wednesday a new version of its humanoid robot, “Atlas,”…

Senate passes defense policy bill with 5.2% pay raise for troops, the biggest boost in decades

WASHINGTON — The Senate passed a defense policy bill Wednesday that authorizes…